Comparison 2. Treatment: Oscillococcinum versus placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Absence of symptoms at 48 hours ‐ patient assessment	2	796	Risk Ratio (M‐H, Fixed, 95% CI)	1.86 [1.27, 2.73]
2 Absence of symptoms at 48 hours ‐ patient assessment ‐ by age	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
3 Absence of symptoms at 48 hours ‐ patient assessment ‐ by severity of symptoms	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
4 Fitness for work at 2 days	1	334	Risk Ratio (M‐H, Fixed, 95% CI)	1.8 [0.99, 3.26]
5 Fitness for work at 4 days	1	334	Risk Ratio (M‐H, Fixed, 95% CI)	1.04 [0.83, 1.30]
6 No chills at 48 hours	2	418	Risk Ratio (M‐H, Random, 95% CI)	1.30 [1.04, 1.63]
7 No fever at 48 hours	1	88	Risk Ratio (M‐H, Fixed, 95% CI)	1.98 [1.34, 2.92]
8 No rhinitis at 48 hours	1	51	Risk Ratio (M‐H, Fixed, 95% CI)	1.33 [0.66, 2.70]
9 No general aches at 48 hours	1	83	Risk Ratio (M‐H, Fixed, 95% CI)	1.73 [1.16, 2.59]
10 No headache at 48 hours	1	334	Risk Ratio (M‐H, Fixed, 95% CI)	1.2 [0.88, 1.63]
11 No backache at 48 hours	1	334	Risk Ratio (M‐H, Fixed, 95% CI)	1.27 [1.00, 1.61]
12 No spinal pain at 48 hours	1	334	Risk Ratio (M‐H, Fixed, 95% CI)	1.27 [1.02, 1.58]
13 No muscle pain at 48 hours	1	334	Risk Ratio (M‐H, Fixed, 95% CI)	1.47 [1.10, 1.97]
14 No articular pain at 48 hours	1	334	Risk Ratio (M‐H, Fixed, 95% CI)	1.4 [1.09, 1.80]
15 No night cough at 48 hours	1	58	Risk Ratio (M‐H, Fixed, 95% CI)	1.44 [0.73, 2.84]
16 No day cough at 48 hours	1	73	Risk Ratio (M‐H, Fixed, 95% CI)	2.00 [1.20, 3.31]
17 Temperature at 48 hours	1	300	Mean Difference (IV, Fixed, 95% CI)	‐0.5 [‐0.67, ‐0.33]
18 Improvement in symptoms at 48 hours ‐ physician assessment	1	334	Risk Ratio (M‐H, Fixed, 95% CI)	1.07 [0.98, 1.18]
19 Absence of symptoms at 48 hours ‐ physician assessment	1	334	Risk Ratio (M‐H, Fixed, 95% CI)	1.28 [0.79, 2.06]
20 Absence of symptoms at 3 days ‐ patient assessment	2	796	Risk Ratio (M‐H, Fixed, 95% CI)	1.27 [1.03, 1.56]
21 Absence of symptoms at 4 days ‐ patient assessment	2	796	Risk Ratio (M‐H, Fixed, 95% CI)	1.11 [0.98, 1.27]
22 Absence of symptoms at 5 days ‐ patient assessment	2	796	Risk Ratio (M‐H, Fixed, 95% CI)	1.06 [0.96, 1.16]
23 Increased use of concomitant medication during trial	1	334	Risk Ratio (M‐H, Fixed, 95% CI)	0.61 [0.40, 0.92]
24 Medication used for pain or fever	1	462	Risk Ratio (M‐H, Fixed, 95% CI)	0.82 [0.67, 1.00]
25 Medication used for cough or coryza	1	462	Risk Ratio (M‐H, Fixed, 95% CI)	0.96 [0.76, 1.21]
26 Antibiotics used	1	462	Risk Ratio (M‐H, Fixed, 95% CI)	0.87 [0.47, 1.62]